ADVERTISEMENT
search.svg

Pharmacy News

FDA warns of dental problems associated with certain buprenorphine medications

FDA is drawing attention to dental problems linked to buprenorphine-containing medications that are dissolved under the tongue or placed against the inside of the cheek to treat opioid use disorder and pain.

ISMP issues warning about possible safety issues with newly authorized antiviral

To encourage the appropriate use of Pfizer’s COVID-19 antiviral drug nirmatrelvir/ritonavir (Paxlovid), the Institute for Safe Medication Practices (ISMP) released an alert for dispensing pharmacists.

Study links statins with more aggressive diabetes progression

Patients with diabetes who used statins experienced less control of their diabetes than patients who did not take statins, suggests a new retrospective study published in JAMA Internal Medicine.

FDA puts clozapine REMS requirements on temporary hold

FDA said it is temporarily halting its risk evaluation and mitigation strategy (REMS) program for clozapine, a treatment for schizophrenia.

Update on biosimilars: Recent approvals, role for pharmacists

This year has seen the approval of 2 new biosimilar drugs, including the first biosimilar to earn FDA’s “interchangeable” designation. Byooviz (ranibizumab-nuna) is biosimilar to Lucentis (ranibizumab), a drug for neovascular (wet) age-related macular degeneration (nAMD). Semglee (insulin glargine-yfgn), the first such drug to earn the “interchangeable” distinction, is biosimilar to Lantus (insulin glargine) for diabetes.

RSS
1234